Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 in overweight or obese adults with hyperuricemia
ChiCTR2100049968Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Aug 2021
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperuricemia, obesity and Overweight comparing IBI362 with Placebo / blank control (2 arms). Primary endpoint: Change in blood uric acid from baseline. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
mazdutide
03
Conditions
hyperuricemiaobesityOverweight
Beyond the preview
Go deeper on ChiCTR2100049968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049968.